The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Steve Jobs Had Pancreatic Neuroendocrine Cancer. Learn More. Make a Difference.

Wednesday, October 5, 2011 - 23:26 - Friday, October 7, 2011 - 11:26

The Caring for Carcinoid Foundation mourns the passing of Steve Jobs, one of the most visionary and innovative individuals of our time. Our thoughts and prayers are with his family and loved ones.

Steve’s death, at age 56, is a powerful reminder that cancer knows no bounds. Cancer strikes without warning, without regard for its victims, and all too often, without effective treatments for those affected.

Steve Jobs’ untimely passing reminds us that finding cures is the ultimate weapon in the battle against cancer. Now is the time to shine the spotlight on neuroendocrine cancers and accelerate funding for research in pursuit of cures and effective treatments.

It is critically important to note that pancreatic neuroendocrine cancer, the cancer with which Steve Jobs was diagnosed in 2004, is fundamentally different from pancreatic adenocarcinoma (commonly referred to as “pancreatic cancer”).

The Caring for Carcinoid Foundation (CFCF) is the most focused and deliberate funder of neuroendocrine cancer research. In 2011, CFCF-funded scientists at Johns Hopkins University published pivotal findings about pancreatic neuroendocrine cancer. These findings deepen our understanding of this cancer and will one day lead to effective treatments.

Upon hearing the news of Steve Jobs’ death, CFCF founder Nancy Lindholm stated, “I established the Caring for Carcinoid Foundation in 2005 to fund research in pursuit of cures for neuroendocrine cancers and to eliminate the suffering of patients with these rare cancers. And while we’re making progress, the unspeakably sad passing of Steve Jobs reminds us that progress can’t come fast enough.”

About the Caring for Carcinoid Foundation

The Caring for Carcinoid Foundation is dedicated to discovering cures and effective treatments for carcinoid, pancreatic neuroendocrine (also known as “islet cell”), and related neuroendocrine cancers. Along with its focus on research, CFCF is committed to supporting patients, families, friends, and caregivers by providing them with complete and up-to-date information. CFCF directs 100% of all individual donations to breakthrough scientific research. This is made possible by the generous support of CFCF’s board of directors, corporate sponsors and pro bono legal counsel. Established in 2005, CFCF has awarded more than $6 million in research grants to leading scientists at renowned institutions worldwide. For more information about CFCF or to support this research, please visit http://www.caringforcarcinoid.org or call 617-948-2514.

About Pancreatic Neuroendocrine and related Neuroendocrine Cancers

Neuroendocrine tumors are a type of cancer that can originate almost anywhere in the body. The most common sites from which neuroendocrine tumors arise are the lungs, appendix, small intestine, rectum, and pancreas. Neuroendocrine tumors that arise in the pancreas are called “pancreatic neuroendocrine tumors,” “islet cell tumors,” or “pancreatic endocrine tumors.” When neuroendocrine tumors originate in other areas, they are most commonly classified as “carcinoid cancer.” Currently, there are ~105,000 people living in the United States with neuroendocrine tumors.

Make a Difference Get Involved Today

Sign-up for our e-Newsletter.

E-update Archive

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

video

Latest Video

Check out the CFCF video library.

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange